<?xml version="1.0" encoding="UTF-8"?>
<legaldoc>
<law type="statute"><section id="id200"><amendatorysection statutenumber="71-9602" chaptername="Public Health and Welfare"><bookinfo>Reissue Revised Statutes of Nebraska</bookinfo><statuteno>71-9602</statuteno><catchline>Terms, defined.</catchline><para>For purposes of the Investigational Drug Use Act:</para><para>(1) Advanced illness means any progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of federally approved and available treatments, and that, without life-sustaining procedures, would likely result in death within six months;</para><para>(2) Eligible patient means a person who meets the requirements of section 71-9603;</para><para>(3) Health care provider has the same meaning as in section 71-7907;</para><para>(4) Investigational drug, biological product, or device means any drug, biological product, or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration and remains under investigation in a clinical trial approved by the United States Food and Drug Administration;</para><para>(5) Physician means any person who is licensed to practice medicine and surgery pursuant to the Medicine and Surgery Practice Act; and</para><para>(6) Written, informed consent means a writing which conforms to section 71-9604.</para></amendatorysection></section><source><para>Laws 2018, LB117, &#167; 2. </para><effectivedate>July 19, 2018</effectivedate></source><crossreference><para><emphasis>Medicine and Surgery Practice Act,</emphasis> see section 38-2001.</para></crossreference></law>
</legaldoc>